Danaher Corp. (DHR)

141.01
NYSE : Health Technology
Prev Close 139.35
Day Low/High 139.62 / 141.54
52 Wk Low/High 94.59 / 140.25
Avg Volume 2.38M
Exchange NYSE
Shares Outstanding 715.93M
Market Cap 99.77B
EPS 3.80
P/E Ratio 40.59
Div & Yield 0.68 (0.47%)
Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock

Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock

WASHINGTON, Feb. 25, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has commenced concurrent offerings of $1.

Dow Closes Modestly Higher After Trump Extends China Tariff Deadline

Dow Closes Modestly Higher After Trump Extends China Tariff Deadline

The Dow Jones Industrial Average rose modestly Monday after Donald Trump said he will delay increasing tariffs on China-made goods.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

How to Trade General Electric After $23.4 Billion Asset Sale

How to Trade General Electric After $23.4 Billion Asset Sale

Both Danaher and General Electric stocks are flying higher after the latter agreed to sell its biopharma unit to the latter for $23.4 billion.

Markets Higher as Tariff Deadline Extended, DHR Price Target Update

A trade deal with China would be meaningful for any company that does a solid amount of business in the region, and perhaps more so the stocks tied to global economic growth.

Is General Electric Still a Decent Value Play?

Is General Electric Still a Decent Value Play?

Just because the stock is still down substantially from its all-time highs doesn't mean that it is still 'cheap'.

Video: Jim's Daily Rundown for Monday

Jim breaks down the huge Danaher-GE deal, discusses what to make of CVS after last week's earnings report, talks about what a trade deal could mean for the broader market, and more!

Why Jim Cramer's a Fan of GE Selling Its Biopharma Business to Danaher

Why Jim Cramer's a Fan of GE Selling Its Biopharma Business to Danaher

Here's why Jim Cramer was pleased that General Electric sold its biopharma business to Danaher and what it means for Larry Culp's leadership.

General Electric Sells Biopharma Unit for $21.4 Billion as Culp Unwind Continues

General Electric Sells Biopharma Unit for $21.4 Billion as Culp Unwind Continues

General Electric agreesd to sell the biopharma portion of its life sciences business to Danaher, the firm that GE CEO Larry Culp ran for around 13 years, for $21.4 billion in cash.

Jim Cramer's Thoughts on General Electric's Biopharma Sale and Kraft Heinz

Jim Cramer's Thoughts on General Electric's Biopharma Sale and Kraft Heinz

Jim Cramer has an acquisition idea for Berkshire Hathaway and his reaction to GE's sale of its biopharma sale.

Larry Culp Showed Up at the Right Time for General Electric

Larry Culp Showed Up at the Right Time for General Electric

The question for us though becomes is this, or when is, the right time for investors to create some value for themselves?

Danaher Stock Rises on Huge Acquisition Splash

Overall, this was a fantastic outcome for Danaher and General Electric.

Jim Cramer: Dissecting Kraft Heinz, General Electric and Berkshire Hathaway

Jim Cramer: Dissecting Kraft Heinz, General Electric and Berkshire Hathaway

Curious about Jim Cramer's thoughts on Kraft Heinz after its disappointing quarter? Or his reaction to GE's biopharma sale? What about Berkshire Hathaway's possible acquisition?

Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress

Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress

StocksGlobal stocks traded higher Monday after President Donald Trump said he would delay the increase of tariffs on China-made goods, set to kick-in on March 1, following "substantial progress" over two weeks of trade talks between Washington and Beijing.

Danaher To Acquire The Biopharma Business Of General Electric Life Sciences For $21.4 Billion

Danaher To Acquire The Biopharma Business Of General Electric Life Sciences For $21.4 Billion

WASHINGTON, Feb. 25, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company") announced today that it has entered into a definitive agreement with General Electric Company ("GE") (NYSE: GE) to acquire the Biopharma business of GE...

Weekly Roundup

We made several trades this week as markets edged higher on optimism over a U.S.-China trade deal.

Weekly Roundup

Markets continued to move higher this week.

Danaher To Present At Barclays Industrial Select Conference

Danaher To Present At Barclays Industrial Select Conference

WASHINGTON, Feb. 13, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, and Executive Vice President, Joakim Weidemanis, will be presenting at the Barclays Industrial...

Weekly Roundup

Markets pulled back this week following a strong January.

Super Bowl Stocks: What Company Is the Bill Belichick of Wall Street?

Super Bowl Stocks: What Company Is the Bill Belichick of Wall Street?

The New England Patriots coach might not be glamorous, but he has an unbelievably long track record of winning. Here are four stocks that share some of the same characteristics as Belichick.

Weekly Roundup

It was a big week for earnings and Jerome Powell's Fed.

Danaher Posts Slight Fourth-Quarter Earnings Beat

Danaher Posts Slight Fourth-Quarter Earnings Beat

The industrial and medical device maker beats analysts' adjusted earnings forecasts by a penny.

Advertising and Search Trend Implications for Three of Our Holdings

We will continue to closely monitor trends with Facebook, Alphabet and Amazon.

Video: Jim's Daily Rundown for Tuesday

Jim discusses Danaher's fourth quarter earnings, what to expect from Apple and Amgen when they report earnings after the bell, and much more!

Danaher Beats With Fourth-Quarter Results

Strong results were expected due to the positive preannouncement, but that does not take away from the fact that it was another great year for the company.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Danaher Reports Fourth Quarter And Full Year 2018 Results

Danaher Reports Fourth Quarter And Full Year 2018 Results

WASHINGTON, Jan. 29, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the fourth quarter and full year 2018.

Weekly Roundup

It was another volatile week on Wall Street.

Earnings Are Coming

With 10 portfolio names reporting results in the week ahead, we want to update members on what we believe are the most important aspects of each release.

The Charts of Danaher Are Poised to Make New Highs

The Charts of Danaher Are Poised to Make New Highs

Let's go over the charts and indicators for a good entry point and risk level.

TheStreet Quant Rating: B (Buy)